| | | |
Aβ4–x (029-2)
|
Aβ (IC16)
|
---|
Case
|
Age (years)
|
Braak stage
|
ApoE
|
SP
|
CAA
|
SP
|
CAA
|
Sporadic AD cases
|
AD-1
|
87
|
V
|
3/3
|
++
|
++
|
+++
|
++
|
AD-2
|
83
|
VI
|
4/3
|
+
|
+
|
+++
|
+
|
AD-3
|
78
|
V
|
4/3
|
++
|
+
|
+++
|
++
|
AD-4
|
79
|
IV
|
4/3
|
++
|
+++
|
++
|
+++
|
AD-5
|
82
|
V
|
4/4
|
+
|
+
|
+++
|
++
|
AD-6
|
84
|
IV
|
4/3
|
++
|
++
|
+++
|
+++
|
AD-7
|
85
|
VI
|
3/3
|
(+)
|
−
|
+++
|
++
|
AD-8
|
92
|
IV
|
3/3
|
+
|
+
|
++
|
+
|
AD-9
|
92
|
IV
|
4/2
|
+
|
++
|
+++
|
++
|
AD-10
|
73
|
IV
|
4/4
|
+
|
++
|
+++
|
+++
|
AD-11
|
92
|
IV
|
3/3
|
++
|
+
|
+++
|
++
|
AD-12
|
93
|
IV
|
3/3
|
+++
|
(+)
|
+++
|
(+)
|
AD-13
|
81
|
IV
|
n.d.
|
++
|
++
|
+++
|
+++
|
AD-14
|
95
|
IV
|
3/3
|
+
|
−
|
++
|
−
|
AD-15
|
91
|
IV
|
4/3
|
+
|
+
|
+++
|
+
|
AD-16
|
65
|
VI
|
3/3
|
(+)
|
−
|
++
|
−
|
AD-17
|
79
|
V
|
3/3
|
+
|
+
|
++
|
+
|
Nondemented control cases
|
NDC-1
|
87
|
II
|
n.d.
|
−
|
−
|
−
|
−
|
NDC-2
|
90
|
I
|
2/2
|
+
|
+
|
++
|
++
|
NDC-3
|
79
|
II
|
4/3
|
+
|
−
|
++
|
−
|
NDC-4
|
89
|
III
|
n.d.
|
−
|
+
|
−
|
+
|
NDC-5
|
78
|
I
|
3/3
|
−
|
+
|
(−)
|
−
|
NDC-6
|
82
|
I
|
3/3
|
−
|
−
|
−
|
−
|
Down syndrome
|
DS-1
|
64
|
V
|
3/3
|
++
|
++
|
+++
|
+++
|
DS-2
|
58
|
VI
|
4/3
|
++
|
+++
|
+++
|
+++
|
-
Abbreviations: Aβ Amyloid-β, AD Alzheimer’s disease, ApoE Apolipoprotein E, CAA Cerebral amyloid angiopathy, DS Down syndrome, NDC Nondemented control subject, SP Senile plaques
- The following semiquantitative scoring criteria were used: − no staining, (+) barely detectable staining, + weak staining, ++ moderate staining, +++ extensive staining